Capmatinib

136 interactions 289 cited references
Also sold as: Tabrecta Tabrecta®
About Capmatinib

Capmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread… Read the full Capmatinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Typhoid Vaccine Bacillus Of Calmette And Guerin Vaccine, Live Varicella Virus Vaccine, Live Smallpox Monkeypox Vaccine Yellow Fever Vaccine
11 Contraindicated 120 Major 5 Moderate
All (136) Contraindicated (11) Major (120) Moderate (5)

Major

Capmatinib Ondansetron Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ozanimod Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Paclitaxel Abraxane Increased PACLitaxel exposure Details Capmatinib Paclitaxel Protein-Bound Increased PACLitaxel exposure Details Capmatinib Phenobarbital Fidoquel Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Phenytoin Dilantin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Pibrentasvir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Pimozide Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Capmatinib Pirfenidone Esbriet Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Posaconazole Noxafil Increased posaconazole exposure and an increased capmatinib exposure Details Capmatinib Primidone Mysoline Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Propranolol Hemangeol Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ramelteon Rozerem Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ranolazine Aspruzyo Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Capmatinib Repotrectinib Augtyro Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Capmatinib Rifabutin Mycobutin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Rifampin Rifadin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Riluzole Exservan Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Rivaroxaban Xarelto Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Ropivacaine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Rosuvastatin Crestor Increased rosuvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Capmatinib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Sirolimus Felycin Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Sofosbuvir Sovaldi Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib St John's Wort Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Sulfasalazine Azulfidine Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Tacrine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Talazoparib Talzenna Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Tasimelteon Hetlioz Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Capmatinib Tenofovir Alafenamide Risk of increased adverse reactions Details Capmatinib Theophylline Accurbron® Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tizanidine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Tolvaptan Jynarque Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Topotecan Hycamtin Risk of increased adverse reactions Details Capmatinib Ubrogepant Ubrelvy Risk of increased adverse reactions Details Capmatinib Velpatasvir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Venetoclax Venclexta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Vorasidenib Voranigo Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.